VIREAD Drug Patent Profile

When do Viread patents expire, and when can generic versions of Viread launch?

Viread is a drug marketed by Gilead Sciences Inc and is included in two NDAs.

The generic ingredient in VIREAD is tenofovir disoproxil fumarate. There are forty-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the tenofovir disoproxil fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viread

A generic version of VIREAD was approved as tenofovir disoproxil fumarate by TEVA PHARMS USA on March 18^th, 2015.

Summary for VIREAD

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	91
Patent Applications:	3,543
Drug Prices:	Drug price information for VIREAD
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIREAD
What excipients (inactive ingredients) are in VIREAD?	VIREAD excipients list
DailyMed Link:	VIREAD at DailyMed

See drug prices for VIREAD

Recent Clinical Trials for VIREAD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Université Protestant au Congo	Phase 4
Doris Duke Charitable Foundation	Phase 4
Albert Einstein College of Medicine	Phase 4

See all VIREAD clinical trials

Pharmacology for VIREAD

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Paragraph IV (Patent) Challenges for VIREAD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIREAD	Tablets	tenofovir disoproxil fumarate	150 mg, 200 mg, and 250 mg	021356	1	2012-05-17
VIREAD	Tablets	tenofovir disoproxil fumarate	300 mg	021356	1	2010-01-26

US Patents and Regulatory Information for VIREAD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	POWDER;ORAL	022577-001	Jan 18, 2012		RX	Yes	Yes
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-004	Jan 18, 2012	AB	RX	Yes	No
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-002	Jan 18, 2012	AB	RX	Yes	No

Expired US Patents for VIREAD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-004	Jan 18, 2012
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-003	Jan 18, 2012
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	POWDER;ORAL	022577-001	Jan 18, 2012

International Patents for VIREAD

See the table below for patents covering VIREAD around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2605226	COMPOSITION D'ANALOGUES DE NUCLEOTIDES ET PROCEDE DE SYNTHESE (NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD)
Japan	2007297406	NUCLEOTIDE ANALOG
Taiwan	I224103

Supplementary Protection Certificates for VIREAD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1663240	PA2016044	Lithuania		PRODUCT NAME: RILPIVIRINAS + EMTRICITABINAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621
1419152	122012000038	Germany		PRODUCT NAME: KOMBINATION AUS RILPIVIRIN ODER EINER STEREOCHEMISCH ISOMEREN FORM ODER EINEM PHARMAZEUTISCH UNBEDENKLICHEN ADDITIONSSALZ DESSELBEN, EINSCHLIESSLICH DES CHLORWASSERSTOFFSAEURESALZES VON RILPIVIRIN, UND TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT.; REGISTRATION NO/DATE: EU/1/11/737/001 20111128
2924034	2019018	Norway		PRODUCT NAME: DORAVIRIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV I KOMBINASJON MED LAMIVUDIN OG I KOMBINASJON MED TENOFOVIRDISOPROKSIL FUMARAT; REG. NO/DATE: EU/1/18/1333/001-2 20181213

Market Dynamics and Financial Trajectory for VIREAD (Tenofovir Disoproxil Fumarate)

Last updated: January 17, 2026

Executive Summary

VIREAD (tenofovir disoproxil fumarate, TDF), developed by Gilead Sciences, is a first-generation nucleotide reverse transcriptase inhibitor (NRTI) primarily used in treating chronic hepatitis B virus (HBV) infection and Human Immunodeficiency Virus (HIV) infections. Since its launch in 2001, VIREAD has experienced significant market penetration, driven by increasing HIV and HBV prevalence, evolving treatment guidelines, and expanding global access initiatives. However, recent patent expirations and the advent of new formulations and alternatives are reshaping its financial and market landscape.

This comprehensive assessment details the complex market dynamics and financial trajectory of VIREAD, emphasizing key factors such as demand drivers, competitive pressures, regulatory environments, patent expiration impacts, and anticipated future trends.

---

What Are the Core Market Drivers for VIREAD?

Factor	Details	Implications
Global HIV Epidemiology	Approximately 38 million people living with HIV globally (UNAIDS, 2022).	Consistent high demand, especially in low- and middle-income countries (LMICs).
Chronic HBV Prevalence	Over 296 million worldwide, with a significant subset requiring antiviral therapy.	Expands potential market beyond HIV.
Treatment Guidelines	U.S. DHHS and WHO recommend tenofovir-based regimens as first-line treatments for HIV and HBV.	Ensures sustained demand, bolstered by authoritative directives.
Pediatric and Migrant Populations	Increasing cases necessitate long-term therapy options.	Assures continual usage of TDF formulations.
Global Access Programs	Gilead’s licensing agreements and generic manufacturing in LMICs enhance reach.	Amplifies sales volume and geographic coverage.

---

How Have Patent and Regulatory Frameworks Shaped VIREAD’s Market?

Milestone	Date	Impact on Market
Initial FDA Approval	Oct 2001	Entry into the HIV treatment market, capturing early demand.
Patent Expiry in US	March 2020	Exposure to generic competition, leading to significant price erosion.
Patent Expiry in Europe	2023	Similar effects observed in EU markets.
U.S. Patent Disputes & Extensions	2010-2018	Delayed generic entry, maintained premium pricing temporarily.
Transition to TAF (Tenofovir Alafenamide)	2015 onward	Shift towards newer formulations, reducing VIREAD’s market share.

Note: Patent protections and regulatory data significantly influence price points, sales volumes, and competitive positioning.

---

What Are the Competitive and Market Alternatives?

Product/Approach	Type	Approval Dates	Key Features	Market Position
VIREAD (TDF)	First-generation NRTI	2001 (FDA)	Widely used, well-established	Market leader, early adopter
VICTRELIS (TDF)	Generic TDF	Post-2020 (after patent expiry)	Cost-effective, reduced prices	Intensified competition
TAF-Based Drugs (e.g., VEMLidy, Genvoya)	Advanced formulations	2015 onward	Improved safety profiles, lower renal/bone toxicity	Growing preference in markets with safety concerns
Descovy (TAF)	TAF-based	2016 (FDA)	Alternative to VIREAD with better tolerability	Emerging market share, prescriber shifts
Novel NRTIs and Integrase Inhibitors	Next-generation drugs	Ongoing	Superior safety/effectiveness	Potential long-term competition

---

Financial Trajectory Analysis: Revenue, Pricing, and Market Share

Historical Revenue Trends

Year	Estimated Global Sales (USD Millions)	Notes
2001	~$500	Launch phase, limited by prescription volume.
2010	~$1.8B	Expanded global uptake; increased HIV prevalence.
2019	~$3.2B	Peak sales; patent protection secured.
2020	~$2.8B	Patent expiry impacts; beginning of generic penetration.

Pricing Dynamics Post-Patent Expiry

Market	Pre-Patent Expiry Price (per 300 mg tablet USD)	Post-Patent Generic Price (USD)	Price Reduction (%)
US	~$30	<$10	66%
Europe	~$35	~$12	65%
Global (LMICs via licensing)	~$10	<$2	>80%

Note: The price reductions directly influence revenue streams, especially in high-volume markets.

Market Share Distribution (2022)

Formulation	Estimated Market Share (HIV)	Estimated Market Share (HBV)	Comments
VIREAD (TDF)	60%	55%	Dominant but declining due to generics and TAF shift
TAF-based Drugs	30%	35%	Growing preference due to safety profiles
Others	10%	10%	Less prevalent, includes non-tenofovir options

---

What Is the Future Outlook for VIREAD’s Market and Revenue?

Market Resilience Factors

• Continued demand in LMICs: Gilead’s licensing agreements maintain market presence in Africa, Asia, and Latin America.
• Chronic disease prevalence: Long-term treatment remains necessary for HIV/HBV.
• Generics and Pricing: Price reductions may cap revenue growth but sustain volume.

Decline Drivers

• Patent expiration impact: Shift towards generics reduces unit prices.
• Preference for TAF formulations: Higher safety and tolerability lead physicians to prescribe newer options.
• Regulatory approvals: Increasing restrictions based on safety data.

Projected Revenue Trends (Next 5-10 Years)

Scenario	Assumptions	Projected Revenue (USD Millions)	Timeframe
Conservative (Low)	Rapid generic penetration, slow adoption of TAF	~$1B	2023-2030
Base Case	Gradual market shift, maintained demand in LMICs	~$1.5B	2023-2030
Optimistic	Slow generic entry, strong access programs	~$2B	2023-2030

---

Comparison: VIREAD vs. Next-Generation NRTIs and Formulations

Aspect	VIREAD (TDF)	TAF-Based Drugs	Novel NRTIs
Safety Profile	Moderate	Superior (less renal/bone toxicity)	Emerging, variable safety profiles
Efficacy	High	Comparable	Variable
Cost	Lower (post-patent expiry)	Generally higher	Varies, still under development
Patent Status	Expired/Expiring	Valid	Pending

---

Key Market and Financial Risks

Risk Factors	Details	Mitigation Strategies
Patent Litigation	Delays generic entry	Active patent defense, licensing deals
Regulatory Changes	Tighter safety approvals	Investment in safety data, reformulations
Competition	TAF and newer drugs	Accelerate adoption of TAF formulations
Pricing Pressures	Global price cuts	Expand access programs & optimize supply chain

---

Conclusion: Strategic Considerations for Stakeholders

• Gilead Communications: Emphasize safety and efficacy benefits of TAF, diversify revenue streams, and leverage licensing and access programs.
• Investors: Monitor generic entry timelines, patent litigations, and adoption rates of newer formulations.
• Healthcare Providers: Balance drug safety profiles with patient-specific factors, especially in high-risk populations.
• Policy Makers & Donors: Support affordable access initiatives, especially in LMICs, to sustain demand.

---

Key Takeaways

• VIREAD has dominated the HIV and HBV markets for over two decades, but patent expirations have precipitated significant revenue declines.
• The shift toward TAF-based formulations offers improved safety but challenges VIREAD’s dominance.
• Global access programs and licensing have extended VIREAD’s market presence in LMICs, maintaining volume despite falling prices.
• Revenue forecasts project potential declines unless innovation or market expansion strategies are implemented.
• Stakeholders should prioritize safety, access, and innovative formulation development to navigate competitive pressures and evolving regulations.

---

FAQs

1. When did VIREAD’s patent protections expire in major markets?
   The primary U.S. patent for VIREAD expired in March 2020, with European patents expiring in 2023, opening the market to generics.

2. How does VIREAD compare to TAF-based drugs in terms of safety?
   TAF formulations generally exhibit lower renal toxicity and bone mineral density impacts, making them preferable for long-term therapy.

3. What impact have generics had on VIREAD’s sales?
   Generics have caused a significant decline in VIREAD’s average selling price, reducing revenue but increasing volume in certain markets, especially LMICs.

4. Are there ongoing patent disputes affecting VIREAD’s market?
   Yes, patent disputes and extensions historically delayed generic entry, but most protections have now expired.

5. What is the outlook for VIREAD in the upcoming decade?
   Expect continued decline in developed markets with robust demand remaining in LMICs. Growth hinges on licensing, access programs, and potential reformulations.

---

References

1. UNAIDS. Global AIDS Update 2022.
2. Gilead Sciences. VIREAD Product Overview and Patents.
3. U.S. Food & Drug Administration. Approved Drugs Database.
4. World Health Organization. HIV & HBV treatment guidelines.
5. Market research reports (2022). Global antiviral drug Market Dynamics.